Back to Search Start Over

Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass.

Authors :
Gibert, Audrick
Lanoiselée, Julien
Gouin-Thibault, Isabelle
Pontis, Adeline
Azarnoush, Kasra
Petrosyan, Andranik
Grand, Nathalie
Molliex, Serge
Morel, Jérome
Gergelé, Laurent
Hodin, Sophie
Bin, Valérie
Chaux, Robin
Delavenne, Xavier
Ollier, Edouard
Source :
Clinical Pharmacokinetics. Feb2024, Vol. 63 Issue 2, p211-225. 15p.
Publication Year :
2024

Abstract

Background: Unfractionated heparin (UFH) is commonly used during cardiac surgery with a cardiopulmonary bypass to prevent blood clotting. However, empirical administration of UFH leads to variable responses. Pharmacokinetic and pharmacodynamic modeling can be used to optimize UFH dosing and perform real-time individualization. In previous studies, many factors that could influence UFH pharmacokinetics/pharmacodynamics had not been taken into account such as hemodilution or the type of UFH. Few covariates were identified probably owing to a lack of statistical power. This study aims to address these limitations through a meta-analysis of individual data from two studies. Methods: An individual patient data meta-analysis was conducted using data from two single-center prospective observational studies, where different UFH types were used for anticoagulation. A pharmacodynamic/pharmacodynamic model of UFH was developed using a non-linear mixed-effects approach. Time-varying covariates such as hemodilution and fluid infusions during a cardiopulmonary bypass were considered. Results: Activities of UFH's anti-activated factor/anti-thrombin were best described by a two-compartment model. Unfractionated heparin clearance was influenced by body weight and the specific UFH type. Volume of distribution was influenced by body weight and pre-operative fibrinogen levels. Pharmacodynamic data followed a log-linear model, accounting for the effect of hemodilution and the pre-operative fibrinogen level. Equations were derived from the model to personalize UFH dosing based on the targeted activated clotting time level and patient covariates. Conclusions: The population model effectively characterized UFH's pharmacokinetics/pharmacodynamics in cardiopulmonary bypass patients. This meta-analysis incorporated new covariates related to UFH's pharmacokinetics/pharmacodynamics, enabling personalized dosing regimens. The proposed model holds potential for individualization using a Bayesian estimation. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03125963
Volume :
63
Issue :
2
Database :
Academic Search Index
Journal :
Clinical Pharmacokinetics
Publication Type :
Academic Journal
Accession number :
175279733
Full Text :
https://doi.org/10.1007/s40262-023-01334-3